Department of Neurology with Experimental Neurology, Neuroscience Clinical Research Center, Charité Universitätsmedizin Berlin, Berlin, Germany.
GENESIS Department, Federico II University of Naples, Naples, Italy.
Eur J Neurol. 2024 Jul;31(7):e16280. doi: 10.1111/ene.16280. Epub 2024 Mar 24.
Regular and consistent disease assessment could provide a clearer picture of burden in generalised myasthenia gravis (gMG) and improve patient care; however, the use of assessment tools in practice lacks standardisation. This modified Delphi approach was taken to review current evidence on assessment tool use in gMG and develop expert-derived consensus recommendations for good practice.
A European expert panel of 15 experienced gMG neurologists contributed to development of this consensus, four of whom formed a lead Sub-committee. The PICO (Population, Intervention, Control, Outcomes) framework was used to define six clinical questions on gMG assessment tools, a systematic literature review was conducted, and evidence-based statements were developed. According to a modified Delphi voting process, consensus was reached when ≥70% of the experts rated agreement with a statement as ≥8 on a scale of 1-10.
Eighteen expert- and evidence-based consensus statements based on six themes were developed. Key recommendations include: consistent use of the Myasthenia Gravis Activities of Daily Living score (MG-ADL) across clinical settings, followed by a simple question (e.g., Patient Acceptable Symptom State [PASS]) or scale to determine patient satisfaction in clinical practice; use of a Quantitative Myasthenia Gravis [QMG] or quality of life [QoL] assessment when the MG-ADL indicates disease worsening; and consideration of symptom state to determine the timing and frequency of recommended assessments. Expert panel consensus was reached on all 18 statements after two voting rounds.
This process provided evidence- and expert consensus-based recommendations for the use of objective and subjective assessment tools across gMG research and care to improve management and outcomes for patients.
定期、一致的疾病评估可以更清楚地了解全身性重症肌无力(gMG)的负担,并改善患者的护理;然而,在实践中评估工具的使用缺乏标准化。本项改良 Delphi 方法旨在回顾 gMG 评估工具使用的现有证据,并制定专家共识推荐意见,以指导良好实践。
来自 15 位有经验的 gMG 神经病学家的欧洲专家小组参与了本共识的制定,其中 4 位形成了一个领导小组委员会。采用 PICO(人群、干预、对照、结局)框架定义了 6 个关于 gMG 评估工具的临床问题,进行了系统的文献回顾,并制定了基于证据的陈述。根据改良 Delphi 投票过程,当≥70%的专家对陈述的同意程度进行评分(1-10 分,分值越高表示同意程度越高),且≥8 分时,即达成共识。
基于 6 个主题制定了 18 条基于专家和证据的共识陈述。主要推荐意见包括:在临床环境中一致使用重症肌无力日常生活活动量表(MG-ADL),然后使用简单的问题(例如,患者可接受的症状状态[PASS])或量表来确定患者的满意度;当 MG-ADL 表明疾病恶化时,使用定量重症肌无力[QMG]或生活质量[QoL]评估;考虑症状状态以确定建议评估的时间和频率。在两轮投票后,专家组对所有 18 条陈述达成了共识。
本项研究提供了基于证据和专家共识的建议,以在 gMG 研究和护理中使用客观和主观评估工具,以改善患者的管理和结局。